APLS News & Analysis
2 articles
Market Mood
Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
Roth/MKM downgraded Apellis Pharmaceuticals (APLS) following Biogen's acquisition, citing concerns over competitive pressures. This action reflects broader market sentiment regarding APLS's growth prospects in the wake of the acquisition. Specific data points and projections were not included in the downgrade, leading to uncertainty among investors. The market will be closely monitoring APLS's response and performance in the coming quarters, impacting stock movements and investor confidence.
Read More
Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
Cantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.
Read More